Prostate cancer is a type of cancer that affects a lot of men, and as there is no cure for cancer yet, spotting the symptoms is important. One of the possible indicators of the disease is through another condition, according to a new report.
Express reports that jaundice may also be a possible symptom of prostate cancer among men. Jaundice is referred to as having a yellowish tinge in the skin, as well as the whites of the eyes. This is caused by issues with the liver, and this condition would mean that the cancer has already progressed and spread towards the liver, where there may be some problems with the bile duct or large parts of the liver that have already been affected.
Jaundice is not the only indication that the cancer has already affected the liver. Other indicators include a pain on the right side of the body, nausea, loss of appetite, weight loss, itchy skin, as well as a swollen tummy.
Another possible indicator of prostate cancer is found in the urine. Express also reports that seeing a pink, red, or brownish-red color in the urine may be a symptom of prostate cancer. This would mean that there is blood. The same applies if there is blood in the semen, as the prostate is responsible for the production of semen, the fluid that is carrying the sperm. According to Cancer News Today, finding blood in the urine is also known as hematuria, and it can indicate that the prostate cancer has progressed.
However, because these are merely symptoms, there is a big chance that it may indicate other conditions that are not as severe as prostate cancer. Still, in case these are seen, then it is highly advised to consult a doctor to get a proper diagnosis and treatment. The earlier this is detected, the more successful treatment will be.
Prostate cancer mainly affects men above the age of 50, and the usual time of diagnosis between men is from 65 to 69. The risk of developing prostate cancer increases among men if there is a family history of either prostate or breast cancer.


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 



